Nichtepitheliale Ovarialmalignome

Ovarialkarzinome sind in der Mehrheit epithelialen Ursprungs. Die nicht epithelialen Typen umfassen seltene Entitäten, die auch junge Frauen im reproduktionsfähigen Alter betreffen können. Ein potenzieller Fertilitätserhalt ist deshalb bei der Therapie zu berücksichtigen. Um die unterschiedlichen Tumorarten zu verstehen und die richtige Therapie einzuleiten, ist die Kenntnis der unterschiedlichen Zelltypen des Ovars sehr wichtig.

Schlüsselwörter

Keimstrangstromatumore - Keimzelltumore - Diagnostik - Therapie - Leitlinie

• Literatur

• 1 Kurman RJ, Carcangiu ML, Herrington CS, Young RH. World Health Organisation Classification of Tumours of the female reproductive Organs. Lyon: International Agency for Research on Cancer (IARC); 2014
• 2 Schünke M, Schulte E, Schumacher U, Voll M, Wesker KH. Inneres weibliches Genitale: Eierstock (Ovarium) und Follikelreifung. In: Schünke M, Schulte E, Schumacher U. Prometheus LernAtlas – Innere Organe. Stuttgart: Thieme; 2009
• 3 Zentrum für Krebsregisterdaten. Ovarian cancer. Accessed August 25, 2021 at: https://www.krebsdaten.de/Krebs/EN/Content/Cancer_sites/Ovarian_cancer/ovarian_cancer_node.html
• 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 5.0, AWMF-Registernummer: 032/035OL. 2021 Accessed August 25, 2021 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/
• 5 Chen VW, Ruiz B, Killeen JL. et al. Pathology and classification of ovarian tumors. Cancer 2003; 97: 2631-2642
• 6 Trétarre B, Molinié F, Woronoff AS. et al. Ovarian cancer in France: Trends in incidence, mortality and survival, 1980–2012. Gynecol Oncol 2015; 139: 324-329
• 7 Kommoss F, Lehr HA. Keimstrang-Stromatumoren des Ovars. Pathologe 2019; 40: 61-72
• 8 Sessa C, Schneider DT, Planchamp F. et al. ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncol 2020; 21: e360-e368
• 9 Polterauer S, Grimm C, Kölbl H. et al. Seltene maligne Ovarialtumore. Frauenheilkunde up2date 2013; 7: 191-206
• 10 Marth C, Reimer D, Zeimet A. Die nicht epithelialen Malignome des Ovars. Frauenheilkunde up2date 2011; 5: 341-355
• 11 Cardenas C, Alvero AB, Yun BS. et al. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocrine-Related Cancer 2016; 23: R411-R422
• 12 Weyerstahl T, Stauber M. Gynäkologie und Geburtshilfe. Stuttgart: Thieme; 2013
• 13 Sehouli J, Drescher FS, Mustea A. et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004; 24: 1223
• 14 Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol 2017; 28 (Suppl. 08) viii8-viii12
• 15 Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 2015; 39: 983-992
• 16 Schultz KAP, Harris AK, Finch M. et al. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol 2017; 147: 521-527
• 17 Feldman DR, Iyer G, Van Alstine L. et al. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res 2014; 20: 3712-3720
• 18 Kim SY, Ebbert K, Cordeiro MH. et al. Constitutive activation of PI3K in oocyte induces ovarian granulosa cell tumors. Cancer Res 2016; 76: 3851-3861
• 19 Heger S. Verfrühte Pubertät. Frauenheilkunde up2date 2016; 10: 107-116
• 20 Seagle BL, Ann P, Butler S. et al. Ovarian granulosa cell tumor: A National Cancer Database study. Gynecol Oncol 2017; 146: 285-291
• 21 Lobo J, Gillis AJM, Jerónimo C. et al. Human germ cell tumors are developmental cancers: Impact of epigenetics on pathobiology and clinic. Int J Molecular Sci 2019; 20: 258
• 22 Smith HO, Berwick M, Verschraegen CF. et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107: 1075-1085
• 23 Mahdi H, Swensen RE, Hanna R. et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 2011; 105: 493-497
• 24 Abdul Razak AR, Li L, Bryant A. et al. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. Cochrane Database Syst Rev 2011; (03) CD007584
• 25 Brewer M, Gershenson DM, Herzog CE. et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999; 17: 2670-2675
• 26 Mayr D, Schmoeckel E, Höhn AK. et al. Aktuelle WHO-Klassifikation des weiblichen Genitale. Pathologe 2021; 42: 259-269
• 27 Malpica A, Deavers MT, Lu K. et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504
• 28 Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518
• 29 Gershenson DM, Sun CC, Bodurka DC. et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009; 114: 48-52
• 30 Grabowski JP, Harter P, Heitz F. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 2016; 140: 457-462
• 31 Gershenson DM, Bodurka DC, Coleman RL. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35: 1103-1111
• 32 Gershenson DM. Fertility-Sparing Surgery for Malignancies in Women. JNCI Monographs 2005; 34: 43-47
• 33 Harter P, Hauke J, Heitz F. et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One 2017; 12: e0186043